PE20110411A1 - Imidazopiridazinacarbonitrilos como inhibidores de quinasa - Google Patents
Imidazopiridazinacarbonitrilos como inhibidores de quinasaInfo
- Publication number
- PE20110411A1 PE20110411A1 PE2011000814A PE2011000814A PE20110411A1 PE 20110411 A1 PE20110411 A1 PE 20110411A1 PE 2011000814 A PE2011000814 A PE 2011000814A PE 2011000814 A PE2011000814 A PE 2011000814A PE 20110411 A1 PE20110411 A1 PE 20110411A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- cyane
- amino
- imidazopyridazine
- carbonitriles
- Prior art date
Links
- MJQSRSOTRPMVKB-UHFFFAOYSA-N 5h-imidazo[4,5-c]pyridazine Chemical compound C1=NNC2=NC=NC2=C1 MJQSRSOTRPMVKB-UHFFFAOYSA-N 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- -1 AMINO Chemical class 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 abstract 2
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 abstract 2
- 102000052052 Casein Kinase II Human genes 0.000 abstract 1
- 108010010919 Casein Kinase II Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- PJESVVYWPFAJCS-UHFFFAOYSA-N pyridazine-3-carbonitrile Chemical compound N#CC1=CC=CN=N1 PJESVVYWPFAJCS-UHFFFAOYSA-N 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Mobile Radio Communication Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10404508P | 2008-10-09 | 2008-10-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20110411A1 true PE20110411A1 (es) | 2011-06-22 |
Family
ID=41718919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2011000814A PE20110411A1 (es) | 2008-10-09 | 2009-10-08 | Imidazopiridazinacarbonitrilos como inhibidores de quinasa |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US8252795B2 (enExample) |
| EP (1) | EP2350081B1 (enExample) |
| JP (1) | JP5560278B2 (enExample) |
| KR (1) | KR20110075010A (enExample) |
| CN (1) | CN102245609B (enExample) |
| AR (1) | AR073818A1 (enExample) |
| AU (1) | AU2009302360B2 (enExample) |
| BR (1) | BRPI0920135A2 (enExample) |
| CA (1) | CA2739782A1 (enExample) |
| CL (1) | CL2011000777A1 (enExample) |
| CO (1) | CO6361936A2 (enExample) |
| CY (1) | CY1114539T1 (enExample) |
| DK (1) | DK2350081T3 (enExample) |
| EA (1) | EA018163B1 (enExample) |
| ES (1) | ES2426951T3 (enExample) |
| HR (1) | HRP20130787T1 (enExample) |
| IL (1) | IL211693A (enExample) |
| MX (1) | MX2011003304A (enExample) |
| NZ (1) | NZ591712A (enExample) |
| PE (1) | PE20110411A1 (enExample) |
| PL (1) | PL2350081T3 (enExample) |
| PT (1) | PT2350081E (enExample) |
| SI (1) | SI2350081T1 (enExample) |
| SM (1) | SMT201300109B (enExample) |
| TW (1) | TWI491610B (enExample) |
| WO (1) | WO2010042699A1 (enExample) |
| ZA (1) | ZA201102423B (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101981033B (zh) * | 2008-02-06 | 2015-02-04 | 百时美施贵宝公司 | 用作激酶抑制剂的取代的咪唑并哒嗪化合物 |
| TWI491610B (zh) * | 2008-10-09 | 2015-07-11 | 必治妥美雅史谷比公司 | 作為激酶抑制劑之咪唑并嗒腈 |
| TWI541243B (zh) | 2010-09-10 | 2016-07-11 | 拜耳知識產權公司 | 經取代咪唑并嗒 |
| US9587033B2 (en) | 2010-11-15 | 2017-03-07 | University Of Florida Research Foundation, Inc. | Therapeutic and diagnostic applications targeting TNK-1 |
| CA2821829A1 (en) | 2010-12-17 | 2012-06-21 | Bayer Intellectual Property Gmbh | Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| JP5822944B2 (ja) | 2010-12-17 | 2015-11-25 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための２置換イミダゾピラジン |
| WO2012080234A1 (en) | 2010-12-17 | 2012-06-21 | Bayer Pharma Aktiengesellschaft | Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| WO2012148792A1 (en) * | 2011-04-26 | 2012-11-01 | Merck Sharp & Dohme Corp. | Heterocyclic compounds as b-raf inhibitors for treatment of cancer |
| US9512126B2 (en) | 2012-03-14 | 2016-12-06 | Bayer Intellectual Property Gmbh | Substituted imidazopyridazines |
| US20150087687A1 (en) | 2012-03-23 | 2015-03-26 | Dennis Brown | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo |
| TW201414737A (zh) * | 2012-07-13 | 2014-04-16 | 必治妥美雅史谷比公司 | 作爲激酶抑制劑之咪唑并三□甲腈 |
| WO2014020041A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
| TW201437211A (zh) * | 2013-03-01 | 2014-10-01 | Bayer Pharma AG | 經取代咪唑并嗒□ |
| PT3008062T (pt) | 2013-06-11 | 2017-06-07 | Bayer Pharma AG | Derivados de profármaco de triazolopiridinas substituídas |
| CA2928568A1 (en) | 2013-07-26 | 2015-01-29 | Update Pharma Inc. | Combinatorial methods to improve the therapeutic benefit of bisantrene |
| AR097543A1 (es) * | 2013-09-06 | 2016-03-23 | Lexicon Pharmaceuticals Inc | COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO |
| TW201542550A (zh) * | 2013-09-06 | 2015-11-16 | Lexicon Pharmaceuticals Inc | 吡唑并［１，５－ａ］嘧啶基化合物、包含彼之組合物以及使用彼之方法 |
| GB201403536D0 (en) * | 2014-02-28 | 2014-04-16 | Cancer Rec Tech Ltd | Inhibitor compounds |
| US10479793B2 (en) | 2015-11-18 | 2019-11-19 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses |
| EP3474855B1 (en) | 2016-06-24 | 2022-01-26 | Polaris Pharmaceuticals, Inc. | Ck2 inhibitors, compositions and methods thereof |
| JP7118002B2 (ja) * | 2016-08-10 | 2022-08-15 | 武田薬品工業株式会社 | 複素環化合物 |
| CN110191887B (zh) | 2016-11-17 | 2022-02-18 | 百时美施贵宝公司 | IL-12、IL-23和/或IFN-α的咪唑并哒嗪调节剂 |
| US20180282282A1 (en) | 2017-03-30 | 2018-10-04 | Genentech, Inc. | Isoquinolines as inhibitors of hpk1 |
| US11339157B1 (en) | 2017-10-24 | 2022-05-24 | Bayer Aktiengesellschaft | 4H-pyrrolo[3,2-c]pyridin-4-one derivatives |
| WO2019128871A1 (zh) | 2017-12-29 | 2019-07-04 | 江苏中旗科技股份有限公司 | N-烷基-n-氰基烷基苯甲酰胺类化合物及其应用 |
| WO2019128872A1 (zh) | 2017-12-29 | 2019-07-04 | 江苏中旗科技股份有限公司 | 一种具有杀虫活性的吡唑酰胺类化合物及其应用 |
| CN109988150B (zh) | 2017-12-29 | 2022-04-12 | 江苏中旗科技股份有限公司 | N-烷基-n-氰基烷基苯甲酰胺类化合物及其应用 |
| IL312674A (en) * | 2018-01-29 | 2024-07-01 | Merck Patent Gmbh | GCN2 inhibitors and uses thereof |
| IL279977B2 (en) | 2018-07-09 | 2024-06-01 | Boehringer Ingelheim Animal Health Usa Inc | Heterocyclic anthelmintic compounds |
| US11612606B2 (en) | 2018-10-03 | 2023-03-28 | Genentech, Inc. | 8-aminoisoquinoline compounds and uses thereof |
| KR102865925B1 (ko) * | 2019-03-05 | 2025-09-26 | 브리스톨-마이어스 스큅 컴퍼니 | Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물 |
| CA3133100A1 (en) | 2019-03-19 | 2020-09-24 | Boehringer Ingelheim Animal Health USA Inc. | Anthelmintic aza-benzothiophene and aza-benzofuran compounds |
| BR112021019998B1 (pt) | 2019-04-24 | 2024-01-16 | The Broad Institute, Inc. | 4h-pirrolo[3,2-c]piridin-4-ona, seus usos, composição farmacêutica, e kit de partes |
| WO2020216774A1 (en) | 2019-04-24 | 2020-10-29 | Bayer Aktiengesellschaft | 4h-pyrrolo[3,2-c]pyridin-4-one derivatives |
| WO2020216773A1 (en) | 2019-04-24 | 2020-10-29 | Bayer Aktiengesellschaft | 4h-pyrrolo[3,2-c]pyridin-4-one compounds |
| CA3177214A1 (en) | 2020-03-31 | 2021-10-07 | Bayer Aktiengesellschaft | 3-(anilino)-2-[3-(3-alkoxy-pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one derivatives as egfr inhibitors for the treatment of cancer |
| MX2022015038A (es) | 2020-05-29 | 2023-01-04 | Boehringer Ingelheim Animal Health Usa Inc | Compuestos heterociclicos como anthelminticos. |
| IL304906A (en) * | 2021-02-03 | 2023-10-01 | Sanofi Sa | DERIVATIVES OF IMIDAZO[4,5-d]PYRIDAZINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
| IL312412A (en) | 2021-11-01 | 2024-06-01 | Boehringer Ingelheim Vetmedica Gmbh | Pyrrolopyridazine compounds against worms |
| WO2023147372A1 (en) * | 2022-01-25 | 2023-08-03 | Kinnate Biopharma Inc. | Inhibitors of cdk4/6 kinase |
| WO2024039767A1 (en) * | 2022-08-18 | 2024-02-22 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Imidazo[1,2-b]pyridazine inhibitors of cyclin-dependent kinases |
| CN115947756B (zh) * | 2022-12-13 | 2025-08-01 | 西湖大学 | 一种芳基卤代物和多氟烷基醇直接偶联合成多氟烷基芳基醚的方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2263566C (en) | 1996-08-28 | 2003-09-09 | Pfizer Inc. | Substituted 6,5-hetero-bicyclic derivatives |
| ES2244613T3 (es) | 2000-04-27 | 2005-12-16 | Astellas Pharma Inc. | Derivados de imidazopiridina. |
| WO2004017950A2 (en) | 2002-08-22 | 2004-03-04 | Piramed Limited | Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents |
| ES2624353T3 (es) | 2002-11-15 | 2017-07-13 | Idenix Pharmaceuticals Llc | 2'-Metil nucleósidos en combinación con interferón y mutación de Flaviviridae |
| BRPI0418328A (pt) * | 2003-12-31 | 2007-05-02 | Schering Plough Ltd | controle de parasitas em animais pelo uso de derivados de imidazo [1,2-b]piridazina |
| CA2555263A1 (en) | 2004-02-12 | 2005-09-01 | Neurogen Corporation | Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands |
| CN101048158A (zh) * | 2004-08-13 | 2007-10-03 | 健泰科生物技术公司 | 利用atp的酶的噻唑－类抑制剂 |
| US20080167314A1 (en) * | 2004-12-28 | 2008-07-10 | Osamu Uchikawa | Condensed Imidazole Compound And Use Thereof |
| AR056191A1 (es) | 2005-08-23 | 2007-09-26 | Idenix Phatmaceuticals Inc | Anillo de nucleosidos de siete miembros como inhibidores de la replica viral, metodos para su sintesis, composiciones farmaceuticas que los contienen y su uso en el tratamiento de infecciones con virus de la familia flaviviridae |
| WO2007025090A2 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase |
| WO2007035428A1 (en) | 2005-09-15 | 2007-03-29 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| US20070078136A1 (en) * | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| US7723336B2 (en) | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| US7547782B2 (en) | 2005-09-30 | 2009-06-16 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| PE20121506A1 (es) | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
| KR20090047509A (ko) * | 2006-08-04 | 2009-05-12 | 다케다 야쿠힌 고교 가부시키가이샤 | 융합 헤테로시클릭 유도체 및 이의 용도 |
| EP1900739A1 (en) | 2006-08-30 | 2008-03-19 | Cellzome Ag | Diazolodiazine derivatives as kinase inhibitors |
| US20110021513A1 (en) | 2006-09-07 | 2011-01-27 | Biogen Idec Ma Inc. | Modulators of interleukin-1 receptor-associated kinase |
| WO2008029152A2 (en) | 2006-09-08 | 2008-03-13 | Summit Corporation Plc | Treatment of duchenne muscular dystrophy |
| EP1911451A1 (en) * | 2006-10-10 | 2008-04-16 | INSERM (Institut National de la Santé et de la Recherche Medicale) | Protein-kinase CK2 inhibitors and their therapeutic applications |
| CA2667960A1 (en) * | 2006-10-30 | 2008-05-08 | Novartis Ag | Imidazopyridazines as pi3k lipid kinase inhibitors |
| PE20090215A1 (es) * | 2007-05-09 | 2009-03-30 | Novartis Ag | Compuestos derivados de imidazopiridazinas como inhibidores de cinasa |
| CN101981033B (zh) * | 2008-02-06 | 2015-02-04 | 百时美施贵宝公司 | 用作激酶抑制剂的取代的咪唑并哒嗪化合物 |
| TWI491610B (zh) * | 2008-10-09 | 2015-07-11 | 必治妥美雅史谷比公司 | 作為激酶抑制劑之咪唑并嗒腈 |
-
2009
- 2009-10-01 TW TW098133429A patent/TWI491610B/zh not_active IP Right Cessation
- 2009-10-08 JP JP2011531168A patent/JP5560278B2/ja not_active Expired - Fee Related
- 2009-10-08 DK DK09740573.2T patent/DK2350081T3/da active
- 2009-10-08 US US12/575,589 patent/US8252795B2/en active Active
- 2009-10-08 BR BRPI0920135A patent/BRPI0920135A2/pt not_active IP Right Cessation
- 2009-10-08 PL PL09740573T patent/PL2350081T3/pl unknown
- 2009-10-08 PT PT97405732T patent/PT2350081E/pt unknown
- 2009-10-08 AU AU2009302360A patent/AU2009302360B2/en not_active Ceased
- 2009-10-08 NZ NZ591712A patent/NZ591712A/xx not_active IP Right Cessation
- 2009-10-08 PE PE2011000814A patent/PE20110411A1/es not_active Application Discontinuation
- 2009-10-08 EA EA201100580A patent/EA018163B1/ru not_active IP Right Cessation
- 2009-10-08 EP EP09740573.2A patent/EP2350081B1/en not_active Not-in-force
- 2009-10-08 CA CA2739782A patent/CA2739782A1/en not_active Abandoned
- 2009-10-08 MX MX2011003304A patent/MX2011003304A/es active IP Right Grant
- 2009-10-08 KR KR1020117010394A patent/KR20110075010A/ko not_active Ceased
- 2009-10-08 SI SI200930729T patent/SI2350081T1/sl unknown
- 2009-10-08 CN CN200980149133.2A patent/CN102245609B/zh not_active Expired - Fee Related
- 2009-10-08 WO PCT/US2009/059968 patent/WO2010042699A1/en not_active Ceased
- 2009-10-08 ES ES09740573T patent/ES2426951T3/es active Active
- 2009-10-08 HR HRP20130787AT patent/HRP20130787T1/hr unknown
- 2009-10-09 AR ARP090103910A patent/AR073818A1/es unknown
-
2011
- 2011-03-10 IL IL211693A patent/IL211693A/en not_active IP Right Cessation
- 2011-03-31 ZA ZA2011/02423A patent/ZA201102423B/en unknown
- 2011-04-07 CO CO11043111A patent/CO6361936A2/es active IP Right Grant
- 2011-04-07 CL CL2011000777A patent/CL2011000777A1/es unknown
-
2012
- 2012-07-19 US US13/552,795 patent/US20120283241A1/en not_active Abandoned
-
2013
- 2013-09-30 CY CY20131100844T patent/CY1114539T1/el unknown
- 2013-10-02 SM SM201300109T patent/SMT201300109B/xx unknown
-
2014
- 2014-02-27 US US14/191,861 patent/US9371328B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20110411A1 (es) | Imidazopiridazinacarbonitrilos como inhibidores de quinasa | |
| PE20151249A1 (es) | Derivados de pirazolopirimidina como inhibidores de jak quinasas | |
| PE20110545A1 (es) | Compuestos de triazolopiridina como inhibidores de jak | |
| PE20141974A1 (es) | Compuestos de heterociclilo | |
| PE20120534A1 (es) | PIRIMIDINAS FUSIONADAS COMO INHIBIDORES DE Akt | |
| PE20140378A1 (es) | Compuestos y composiciones como inhibidores de la trk | |
| PE20110387A1 (es) | Aminotriazolo-piridinas como inhibidores de cinasa | |
| PE20110560A1 (es) | NUEVOS DERIVADOS DE TRIAZOLO[4,3-a]PIRIDINA, SU PROCEDIMIENTO DE PREPARACION, SU APLICACION COMO MEDICAMENTOS, COMPOSICIONES FARMACEUTICAS Y NUEVA UTILIZACION PARTICULARMENTE COMO INHIBIDORES DE MET | |
| PE20091408A1 (es) | Compuestos y composiciones como inhibidores de cinasa | |
| PE20090370A1 (es) | Derivados de heterociclo fusionado como inhibidores de quinasa | |
| PE20091268A1 (es) | Derivados heterociclicos como inhibidores de pi3 quinasa | |
| PE20050691A1 (es) | Proceso para preparar carboxamidas 2-aminotiazol-5-aromaticas como inhibidores de la cinasa | |
| PE20140928A1 (es) | Pirazolo[4,3-d]pirimidinas utiles como inhibidores de cinasas | |
| PE20120107A1 (es) | Inhibidores de proteina cinasa | |
| PE20091833A1 (es) | Derivados heterociclicos espiro biciclicos o heterociclicos biciclicos, puenteados, de pirazolo [1,5-a]pirimidinas como inhibidores de quinasas raf y metodos para su preparacion | |
| PE20121352A1 (es) | Derivados de heteroarilo que contienen n como inhibidores de cinasa jak3 | |
| PE20090944A1 (es) | PIRIMIDINAS BICICLICAS FUSIONADAS COMO INHIBIDORES DE LA VIA Pi3K/AKT | |
| PE20140975A1 (es) | Derivados de imidazopirazina como inhibidores de syk | |
| PE20140927A1 (es) | Compuestos heterociclicos como inhibidores de cinasas | |
| PE20110944A1 (es) | DERIVADOS DE PIRAZOLO[3,4-d]PIRIMIDINA COMO INHIBIDORES PDE1 | |
| PE20081888A1 (es) | ANALOGOS DE PIRAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE CINASA mTOR Y CINASA PI3 | |
| PE20150153A1 (es) | 7H-PIRROLO[2,3-d]PIRIMIDINAS 4-(AMINO-SUBSTITUIDAS) NOVEDOSAS COMO INHIBIDORES DE LRRK2 | |
| PE20120224A1 (es) | Derivados de 1h-imidazo-[4,5-c]-quinolinona | |
| PE20080931A1 (es) | Imidazopirazinas como inhibidores de proteina quinasa | |
| PE20141404A1 (es) | Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |